LEXX

Lexaria is a pre-commercial drug-delivery platform (DehydraTECH) whose economics don't yet resemble a business. FY2025 revenue was $706K — up 52% but off a trivial base, and choppy across five years ($723K→$255K→$226K→$464K→$706K) with no durable trajectory. Against that, the company posted a -$11.9M net loss (a 105% deterioration YoY) as R&D spending exploded +249% to $8.24M, meaning operating losses are structurally 15-17x revenue (operating margin -1683%). The 99.6% gross margin is meaningless at this scale; the loss is entirely R&D-driven and there is no commercialized product generating cash. The accumulated deficit is -$63.5M.

The balance sheet is the disqualifier. Cash fell 72% to $1.80M while operating cash flow was -$10.5M — a burn rate that leaves roughly two months of runway. Management effectively concedes the dependence on external capital: the MD&A states programs 'having been funded by the proceeds of Lexaria's combined 2024 and 2025 financing activities of approximately $16 million' and that to advance the Phase 1(b) hypertension study 'We will need to raise sufficient funding or enter into a collaboration to be in a position to proceed.' Shares already grew 27% in a year; further dilution (or a collaboration on unfavorable terms) is not a risk but a near-certainty, and existing holders will bear it.